Abstract

Background: Recurrent eyelid sebaceous carcinoma (SC) after primary resection still remains a great challenge for ophthalmologists. The predictors of recurrence are multifactorial, the identification of core risk factors to construct an individualized prediction model is warranted. The purpose of this study is to develop and validate a nomogram for individualized recurrence prediction of eyelid SC and to determine the independent risk factors. Methods: A multicenter cohort study. The study included 418 consecutive patients with eyelid SC, and this sample was divided into training (n=293) and validation cohorts (n=125). Least absolute shrinkage and selection operator (LASSO) regression was applied to select the features for the nomogram. The model was evaluated using the receiver operating characteristic (ROC)-derived area under the curve (AUC), calibration plot, and decision-curve analyses (DCAs), and it was compared with the TNM staging system. These results were externally validated with bootstrap resampling in an independent cohort. Multivariate Cox regression was used to explore the independent predictors of recurrence. Findings: This nomogram displayed satisfactory discriminative ability and good calibration for both the training (C-index: 0.83; AUC: 0.84) and validation (C-index: 0.80; AUC: 0.82) cohorts. The discriminative ability compared significantly favorable than TNM staging (C-index: training cohort: 0.67, validation cohort: 0.71; AUC: training cohort: 0.67, validation cohort: 0.71; all p<0.05). DCA demonstrated that this nomogram was clinically useful. Multivariate Cox regression indicated that diagnostic delay (HR=1.01, 95%CI:1.00-1.01, p=0.001), orbital involvement (HR=4.47, 95%CI:3.04-6.58, p<0.001), Ki 67 (HR=1.01, 95%CI:1.00-1.02, p=0.008) and initial surgical modality (HR=0.53, 95%CI:0.35-0.80, p=0.003) were independent predictors of recurrence. Interpretation: This nomogram provides improved individualized estimates of recurrence after primary excision for Chinese patients with eyelid SC. This model may help guide therapeutic decisions in clinical application. Funding Statement: This work was supported by the National Natural Science Foundation of China (Grants No. 81570884, 81770961) and Innovation Fund for Translational Medicine (15ZH1005), and the Shanghai Shuguang Project (14SG18). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Declaration of Interests: The authors state: No conflict of interest to declare. Ethics Approval Statement: The requirement for informed consent was waived by the institutional review board. The research ethics committees of Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine approved this study. This research strictly followed the tenets of the Declaration of Helsinki.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call